Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre A, Bachet J, Boige V, Cayre A, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre A, Bachet J, Boige V, Cayre A, et al.
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets late-stage metastatic melanoma. The medicine contains a gene encoding antigen that may be able to…  
  • More than half of cancer deaths in the U.S. are due to preventable causes.  
  • According to the Pharmaceutical Research and Manufacturers of America, a number of vaccines are being studied that would cause the body’s own immune system to fight cancer after it has…  
  • Low dose CT screening for lung cancer costs less than $200 per person, and surgery for stage I lung cancer is less than 1/2 the cost of late-stage treatment.  
  • Following the current path, breast cancer incidence rate will increase by 50.8% between 2003 and 2023. If an alternative path is taken, cases will increase by 32.2% between 2003 and…